MAP1LC3B and Cerebral ischemia: This study suggests that XXMD exerts neuroprotective effects by down-regulating the expression levels of LC3B, Beclin1, and Lamp1 proteins, thereby reducing mitochondrial activation and improving mitochondrial function in cerebral ischemia-reperfusion injury.